Baird raised the firm’s price target on Apellis to $105 from $90 and keeps an Outperform rating on the shares. The analyst is incrementally positive on broad label for Syfovre in GA (geographic atrophy) and believes the label is the best case scenario with its broad indication, flexible dosing, and strong 24-month data.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly
See today’s best-performing stocks on TipRanks >>
Read More on APLS:
- Apellis Pharmaceuticals Reports Fourth Quarter and Full Year 2022 Financial Results
- Apellis price target raised to $91 from $86 at Citi
- Apellis rally on approval ‘might fade,’ says Wells Fargo
- Iveric now has ‘clearer path towards approval,’ says BofA
- FDA Approves SYFOVRE™ (pegcetacoplan injection) as the First and Only Treatment for Geographic Atrophy (GA), a Leading Cause of Blindness